AI Science Tracker

AI additional reader found 0.7-1.6 extra cancers per 1,000 in prospective Hungarian mammography screening rollout

Kheiron Medical Technologies · 16 Nov 2023 · medicine

Discovery

AI additional reader found 0.7-1.6 extra cancers per 1,000 in prospective Hungarian mammography screening rollout

Source check: Needs source check. Not independent scientific confirmation.

Finding: Ng et al. prospectively assessed a commercial AI system as an additional reader beside standard double reading in three rollout phases (about 25,000 women, four sites), finding 0.7-1.6 additional cancers per 1,000 cases, 0.16-0.30 percent additional recalls and a 0.1-1.9 percent gain in positive predictive value after 7-11 percent additional human reads. Most extra cancers were invasive and small. Authors are from the vendor, Kheiron Medical Technologies; there is no randomization or mortality outcome, and the extra reading workload is part of the result. Abstract-level review.

Technology: Commercial deep-learning mammography reader (vendor system)

Publication: Peer-reviewed paper · Test context: prospective or independent check. Catalog categories, not an evidence grade.

AI contribution
The AI flagged cases for arbitration review in addition to two human readers.
Test and result
Performance was assessed prospectively across a pilot, a multicentre pilot and a live rollout (per abstract).
Limitation / still unknown
Long-term outcomes, interval cancers and independent evaluation were not assessed.
Evidence sources and annotation context

Evidence context (descriptions follow the cited sources; test type is a catalog classification):

Evidence sources: https://europepmc.org/article/MED/37973948

Needs source check · editorial details

The source has not been fully checked or contains conflicting information. Independent confirmation is not assessed by this label.

Source type: paper. Paper: not linked in this catalog; this does not mean no paper exists.

Review date: 17 Nov 2026. Review scope: abstract and bibliographic metadata (Europe PMC) only; Methods and full text not assessed.

No follow-up recorded; this is not a claim that no follow-up exists. Follow-up review scope and date are not recorded. No source-supported relationships recorded.

Editorial assessment: Impact 3/5 · Validation 4/5 · Novelty 2/5. Impact and novelty are editorial judgments; validation follows the annotated test type where one exists. Not an evidence grade. Scoring criteria.

Open in the full catalog for filters, charts and related discoveries. Browse medicine discoveries.